Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook
Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.
How this was made
The 30-second read
Why it matters
The partnership and guidance lift provide a catalyst for momentum traders, reinforcing a bullish outlook for the stock.
Market read
A notable price move driven by a fresh pharma AI contract and upgraded guidance, offering immediate trading opportunities.
What to watch
Potential execution risk and reliance on a single large customer could limit upside.
Background
Twist Bioscience reported Q3 FY26 results with 23% YoY revenue growth and raised FY26 revenue guidance, while announcing a new AI data partnership with Eli Lilly.
Ticker impact
Twist Bioscience stock jumped ~10% after announcing a data‑services deal with Eli Lilly’s TuneLab AI platform and raising FY26 revenue guidance.
Expect continued short‑term upside if the deal scales, with potential for further 5‑10% moves on related news.
The contract is with a major pharma player, the stock already reacted strongly, and guidance was upgraded, indicating material impact.
Market effects
Highlights growing AI integration in biotech, may boost other synthetic biology firms.
Positive for US biotech sector, limited broader regional effect.
Shows cross‑industry AI collaboration, relevant to global pharma and AI investors.
Counterpoint
Deal size and revenue impact are unclear; the partnership may not translate to near‑term profitability.
Key entities
- companyTwist Bioscience
Synthetic DNA and NGS tools provider.
- companyEli Lilly
Pharma giant using AI/ML TuneLab platform.
